Where ENZYME is life



EARNINGS PRESENTATION

Q4FY17


Disclaimer



This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section be fore taking any action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company under takes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.

Company Overview





What are enzymes?

Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions.

Advanced uses enzymes to replace chemicals in, and improve efficiency of, a wide variety of industrial processes for its customers.

Company Overview



Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

Mission



It is our mission to see that every human being is able to take advantage of the power of enzymes for wellbeing and leading a healthy life!


Vision



Our vision at Advanced Enzymes is to become the largest, enzyme-based, value provider to consumers and processors globally!

Advanced Enzyme Technologies Limited - A Rising Global Star





Amongst Top **15** Global Enzyme Companies



Manufacturing Units – 7


India - 5 USA - 2



R&D Units - 5

India - 4

USA - 1





65+

Indigenously
Developed Enzymes
& Probiotics



13

Registered Patents*



400+

Proprietary Products

11

Food Enzyme

Dossiers filed with

EFSA



700+

Customers Worldwide

GRAS Dossier

filed with US FDA



45+

International Presence



22+

Years of Fermentation Experience



420

m³ Fermentation Capacity



500+

Employees



509

FY 2013



FY 2017

Board of Directors





Mr. Vasant Rathi
Chairman and Non- Executive Director

Mr. Vasant Laxminarayan Rathi is the Promoter Chairman and Non- Executive Director of our Company. He promoted & incorporated Cal-India in the year 1985 and has been associated with our Company since the year 1993. Mr. Rathi heads our international subsidiaries based in US.



Mr. C L Rathi Managing Director

Mr. Chandrakant Laxminarayan Rathi, is the Promoter and Managing Director of our Company. He is currently responsible for the management of the entire operations of the Company and its Indian subsidiaries, including strategic initiatives of our businesses.



Mrs. Savita Rathi
Whole-time Director

Mrs. Savita Chandrakant Rathi, is the Wholetime Director of our Company. She is responsible for the administration of the Company, management and supervision of Export-Import, Client relationship management and the Human Resource department of the Company.



Mr. Mukund M. Kabra
Whole-time Director

Mr. Mukund Madhusudan Kabra, is the Whole-time Director of our Company. He is responsible for overlooking the manufacturing operations of the Company at Sinnar and Indore and for optimising the fermentation for existing products, strain improvement, downstream research and analytical research.



Mr. Kedar Desai Independent Director

Mr. Kedar Jagdish Desai, is the Independent Director on our Board. He holds a Bachelor's degree in Commerce and Law from the University of Mumbai. He is also a qualified solicitor from the Bombay Incorporated Law Society and has over 19 years of experience in the field of law.



Mrs. Rupa Vora Independent Director

Mrs. Rupa Rajul Vora, is a Non-Executive and Independent Director of our Company since November 28, 2015. She was the Chief Financial Officer at Antwerp Diamond Bank N.V., after which she joined IDFC Group as a Group Director and Chief Financial Officer-Alternatives until June 2014. Currently, she serves as an independent director on a few corporate boards.



Mr. Pramod Kasat
Independent Director

Mr. Pramod Kasat, is a Non-Executive and Independent Director of our Company since December 14, 2016. He is currently the Country Head – Investment banking , Indusind Bank, Mumbai.



Mr. Ramesh Mehta Independent Director

Mr. Ramesh Thakorlal Mehta is a Non-Executive and Independent Director of our Company since 1993. He has experience in the business of jewellery designing and manufacturing.

Management Team





Piyush Rathi Chief Business Officer

A double graduate, Piyush first completed his Bachelors in Maths from Mumbai University and then in Finance from Michigan Tech University, USA. Subsequently he completed his MBA from SCMHRD and joined Advanced Enzymes in April 2005. In 2007 and in 2010, Piyush took charge of the Human Nutrition and Bio-Processing businesses respectively, and since 2014, he has also started developing the Animal Nutrition business internationally. Today, as Chief Business Officer, his key responsibility is to oversee the development of the company's business in Europe & Asia. He has also been instrumental in the recent acquisition of JC Biotech.



Beni Prasad Rauka
Chief Financial Officer

Mr. Beni Prasad Rauka, a Chartered Accountant and Company Secretary by qualification, brings with him a rich experience of over 24 years in the Finance Industry. Mr. Rauka has worked with Category I Merchant Banking firms and finance companies in his long standing career. Mr Rauka joined Advanced Enzymes in the year 2000 as a consultant. Rauka has been leading the financial innovation in the new business structure and managing the financial activities of all group companies since 2007. As Group CFO, his prime objective today is to ensure that adequate and cost-effective finance is available for the group's strategic plans and investments.



Dr. Anil GuptaVice President - Research & Development

Dr. Anil Gupta is a Ph.D. in Microbiology with over 18 years of experience in Industrial Biotechnology. Prior to his joining Advanced Enzymes, he also received the coveted Young Scientist Award Project from Department of Science & Technology, Govt. Of India and has worked as Principal Investigator in several research projects. Today, as Vice President - Research & Development, General Manager Research & Development, Dr. Gupta heads the process development, proteomics & the applied microbiology labs and leads the research effort in developing several new commercially-viable enzymes every year.




Dipak Roda
Vice President - Market & Business
Development


After having secured a Chemical Engineering degree from Bharati Vidyapeeth, Pune and a M.Sc Tech in Bioprocess Technology from UDCT, Mr. Dipak Roda began his career with Khandelwal Laboratories in their bio-technology division. Mr. Roda joined Advanced Enzymes in 2005 as a General Manager in Sales & Marketing. He played a key role in aligning the product baskets to the respective industries that they catered to. He led the company's entry into the large and competitive Chinese market through establishment of Advanced Enzyme Far East. Today, his focus is on growing the bio-processing business in the American continents and his key challenge is to build a strong marketing, sales & distribution network there.

Results Summary – FY17












*YoY Growth



Note: On Consolidated Basis


EBIDTA is including other income


PAT is before minority

Results Summary – Q4FY17










Revenue Breakup ₹ in Million

*YoY Growth




Note: On Consolidated Basis


EBIDTA is including other income

PAT is before minority

Revenue Split







Note: On Consolidated Basis

Profit & Loss (Consolidated) – Q4FY17 & FY17



₹ in Million except per share data

					X 111 IV	illion except p	er strate data
Particulars	Q4FY17 Unaudited	Q3FY17 Unaudited	Q4FY16 Unaudited	Y-o-Y (%)	FY17	FY16	Y-o-Y (%)
Income from Operations	860	600	805	7%	3,314	2,938	13%
Expenses	565	441	432	31%	1,929	1,649	17%
Profit from Operations before Other Income, Finance Costs and Exceptional Item	295	159	373	(21%)	1,385	1,289	7%
Other Income	6	7	6	6%	23	13	77%
Profit from ordinary activities before Finance Costs and Exceptional Item	301	166	379	(21%)	1,408	1,302	8%
Finance costs	12	3	17	(30%)	42	79	(47%)
Profit from ordinary activities before exceptional item and tax	289	163	362	(20%)	1,366	1,223	12%
Exceptional item	-	-	(0.5)	-	-	(41)	-
Profit from ordinary activities before tax	289	163	361	(20%)	1,366	1,182	16%
Tax	89	13	134	(34%)	442	414	7%
Net Profit for the period	200	150	227	(12%)	924	768	20%
Earnings Per Share	9	7	11		41	35	

Balance Sheet (Consolidated) – FY17





₹ in Million


		₹ In IVIIIIIon	
Particulars	FY17	FY16	
EQUITY AND LIABILITIES			
Share capital	223	218	
Reserves and surplus	4,378	2,563	
Minority interest	124	54	
Long-term borrowings	197	388	
Other - Non-current liabilities	191	176	
Short-term borrowings	265	296	
Trade payables	110	115	
Other current liabilities	278	696	
TOTAL- EQUITY AND LIABILITIES	5,766	4,505	
ASSETS			
Fixed assets	4,096	2,924	
Long-term loans and advances	191	180	
Other non-current assets	9	4	
Inventories	685	605	
Trade receivables	510	418	
Cash and bank balances	79	263	
Other current assets	196	111	
TOTAL- ASSETS	5,766	4,505	


Financial Performance – FY17













All numbers are on Consolidated basis


ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax, Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networth)


Strong Financial Performance – FY17











All numbers are on Consolidated basis

Net working capital days =((Trade receivables + inventories – Trade payables)/ Revenue from operations)*365

Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent

Shareholder Information




Stock Data (As on 31st March 2017)

Market Capitalization (₹)	45,992 mn
Shares Outstanding	22.3 mn
Free Float	6.5 mn
Symbol (NSE/ BSE)	ADVENZYMES / 540025
Average Daily Volume	47,801

Face Value: ₹2/-	450 412 400 350
\sim	
·	250
A	200
	10411
Aug 16 Aug 31 Sep 15 Sep 30 Oct 14 Oct 30 Nov 15 Nov 30 Dec 15 Dec 30 Jan 16 Jan 31 Feb 14 Feb 28 Mar 15	Mar 31
2016 2017	
Advance Enzyme NIFTY Pharma	

Note: Data mentioned in this slide is as on 31st March 2017

Top Institutional Holders				
Institutions	OS (%)			
DSP Blackrock Investment Management Co.	3.89			
Motilal Oswal Asset Management Co. Ltd.	1.42			
Reliance Capital Trustee Co. Ltd	1.21			
The Nomura Trust And Banking Co. Ltd.	1.02			
Birla Sun Life Insurance Company Ltd.	0.08			



Source: BSE, Bloomberg

Thank You





Advanced Enzymes

5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200

Fax: + 91-22-25835159